Production of cytotoxic, KIR-negative NK cells from CD34+ cord blood cells with the use of Notch signaling

Transfusion

Volumn 51, Issue SUPPL. 4, 2011, Pages

  Beck, Rose C ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LIGAND; NOTCH RECEPTOR;

ARTICLE; CELL DIFFERENTIATION; CELL EXPANSION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PHENOTYPE; SIGNAL TRANSDUCTION; UMBILICAL CORD BLOOD;

ANTIGENS, CD34; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; FETAL BLOOD; HEMATOPOIETIC STEM CELLS; HUMANS; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LEUKEMIA; MICROSPHERES; RECEPTORS, KIR; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 81055144327     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03377.x     Document Type: Article

References (38)

1. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A,. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-100. (Pubitemid 34229476)
2. DeHart SL, Heikens MJ, Tsai S,. Jagged2 promotes the development of natural killer cells and the establishment of functional natural killer cell lines. Blood 2005; 105: 3521-7. (Pubitemid 40628194)
3. Yokoyama WM,. The dynamic life of natural killer cells. Annu Rev Immunol 2004; 22: 405-29. (Pubitemid 38680428)
4. Cooper MA, Fehniger TA, Caligiuri MA,. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633-40. (Pubitemid 33043908)
5. Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP Jr, Takahashi Y, Suffredini DA, Linehan WM, Caligiuri MA, Childs RW,. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal carcinoma cells. Blood 2004; 104: 170-7. (Pubitemid 38879854)
6. Lanier LL,. NK cell recognition. Annu Rev Immunol 2005; 23: 225-74. (Pubitemid 40563170)
7. Yokoyama WM, Plaougastel BFM,. Immune functions encoded by the natural killer gene complex. Nat Rev Immunol 2003; 3: 304-16. (Pubitemid 37328683)
8. Pende D, Spaggiari GM, Marcenaro S, Martini S, Rivera P, Capobianco A, Falco M, Lanino E, Pierri I, Zambello R, Bacigalupo A, Mingari MC, Moretta A, Moretta L,. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 2005; 105: 2066-73. (Pubitemid 40731793)
9. Costello R, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D, Gastaut JA, Pende D, Olive D, Moretta A,. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002; 99: 3661-7. (Pubitemid 34534536)
10. Verheyden S, Demanet C,. NK cell receptors and their ligands in leukemia. Leukemia 2008; 22: 249-57. (Pubitemid 351250528)
11. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA,. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935-47. (Pubitemid 35001221)
12. Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, Groh V, Spies T, Pollio G, Cosman D, Catalano L, Tassone P, Rotoli B, Venuta S,. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005; 105: 251-8. (Pubitemid 40053090)
13. Siegler U, Kalberer CP, Nowbakht P, Sendelov S, Meyer-Monard S, Wodnar-Filipowicz A,. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice. Leukemia 2005; 19: 2215-22. (Pubitemid 41741617)
14. Ljunggren H-G, Malmberg K-J,. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007; 7: 329-39. (Pubitemid 46674487)
15. Grzywacz B, Miller JS, Verneris MR,. Use of natural killer cells as immunotherapy for leukemia. Best Pract Res Clin Haematol 2008; 21: 467-83.
16. Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, Niethammer D, Handgretinger R,. Determinants of antileukemic effects of allogeneic NK cells. J Immunol 2004; 172: 644-50. (Pubitemid 38020523)
17. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, Urbani E, Negrin RS, Martelli MF, Velardi A,. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333-9. (Pubitemid 29300166)
18. Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL, Guethlein LA, Trachtenberg EA, Haagenson M, Horowitz MM, Klein JP, Weisdorf DJ,. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007; 109: 5058-61. (Pubitemid 46827806)
19. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, Stern M, Pende D, Perruccio K, Burchielli E, Topini F, Bianchi E, Aversa F, Martelli MF, Velardi A,. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007; 110: 433-40. (Pubitemid 47026866)
20. Beelen DW, Ottinger HD, Ferencik S, Elmaagacli AH, Peceny R, Trenschel R, Grosse-Wilde H,. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 2005; 105: 2594-600. (Pubitemid 40387064)
21. Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS, Velardi A, Blazar BR,. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002; 100: 3825-7. (Pubitemid 35303959)
22. Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri MA, Boudreau C, Nelson G, Oudshoorn M, van Rood J, Velardi A, Maiers M, Setterholm M, Confer D, Posch PE, Anasetti C, Kamani N, Miller JS, Weisdorf D, Davies SM,; KIR Study Group, Center for International Blood and Marrow Transplantation Research. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. Biol Blood Marrow Transplant 2006; 12: 876-84. (Pubitemid 44070674)
23. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, Maccario R, Bonetti F, Wojnar J, Martinetti M, Frassoni F, Giorgiani G, Bacigalupo A, Holowiecki J,. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102: 814-9. (Pubitemid 36917769)
24. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB,. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-7.
25. Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, Moreno A, Dupont B, Hsu KC, Baxter-Lowe LA, Cottler-Fox M, Shaughnessy JD Jr, Barlogie B, van Rhee F,. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 2008; 143: 641-53.
26. Passweg J, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kühne T, Favre G, Gratwohl A,. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004; 18: 1835-8. (Pubitemid 39530014)
27. Loren A, Porter DL,. Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation. Curr Opin Oncol 2006; 18: 107-14. (Pubitemid 43740428)
28. Klingemann HG,. Natural killer cell-based immunotherapeutic strategies. Cytotherapy 2005; 7: 16-22.
29. Romagne F, André P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM Jr, Blaser BW, Della Chiesa M, Moretta A, Vivier E, Caligiuri MA, Velardi A, Wagtmann N,. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009; 114: 2667-77.
30. Beck RC, Padival M, Yeh D, Ralston J, Cooke KR, Lowe JB,. The Notch ligands Jagged2, Delta1, and Delta4 induce differentiation and expansion of functional human NK cells from CD34+ cord blood hematopoietic progenitor cells. Biol Blood Marrow Transplant 2009; 15: 1026-37.
31. Suzuki T, Yokoyama Y, Kumano K, Takanashi M, Kozuma S, Takato T, Nakahata T, Nishikawa M, Sakano S, Kurokawa M, Ogawa S, Chiba S,. Highly efficient ex vivo expansion of human hematopoietic stem cells using Delta-1-Fc chimeric protein. Stem Cells 2006; 24: 2456-65. (Pubitemid 44674306)
32. Varnum-Finney B, Brashem-Stein C, Bernstein ID,. Combined effects of Notch signaling and cytokines induce a multiple log increase in precursors with lymphoid and myeloid reconstituting ability. Blood 2003; 101: 1784-9. (Pubitemid 36237574)
33. Maillard I, Fang T, Pear WS,. Regulation of lymphoid development, differentiation, and function by the Notch pathway. Annu Rev Immunol 2005; 23: 945-74. (Pubitemid 40563190)
34. Haraguchi K, Suzuki T, Koyama N, Kumano K, Nakahara F, Matsumoto A, Yokoyama Y, Sakata-Yanagimoto M, Masuda S, Takahashi T, Kamijo A, Takahashi K, Takanashi M, Okuyama Y, Yasutomo K, Sakano S, Yagita H, Kurokawa M, Ogawa S, Chiba S,. Notch activation induces the generation of functional NK cells from human cord blood CD34-positive cells devoid of IL-15. J Immunol 2009; 182: 6168-78.
35. Bachanova V, McCullar V, Lenvik T, Wangen R, Peterson KA, Ankarlo DE, Panoskaltsis-Mortari A, Wagner JE, Miller JS,. Activated Notch supports development of cytokine producing NK cells which are hyporesponsive and fail to acquire NK cell effector functions. Biol Blood Marrow Transplant 2008; 15: 183-94.
36. Porter D, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, Loren A, Phillips J, Nasta S, Perl A, Schuster S, Tsai D, Sohal A, Veloso E, Emerson S, June CH,. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006; 15: 1325-31. (Pubitemid 43242365)
37. Varnum-Finney B, Wu L, Yu M, Brashem-Stein C, Staats S, Flowers D, Griffin JD, Bernstein ID,. Immobilization of Notch ligand, Delta-1, is required for induction of notch signaling. J Cell Sci 2000; 113 (Pt 23): 4313-8. (Pubitemid 32000694)
38. Yan Q, Yao D, Wei LL, Huang Y, Myers J, Zhang L, Xin W, Shim J, Man Y, Petryniak B, Gerson S, Lowe JB, Zhou L,. O-fucose modulates Notch-controlled blood lineage commitment. Am J Pathol 2010; 176: 2921-34.